No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population.
OBJECTIVE
Haplotypes based on polymorphisms in the gene encoding 5-lipoxygenase-activating protein have been linked with susceptibility to myocardial infarction in Iceland and the United Kingdom. We sought to replicate these association findings in a large case-control sample from Germany.


METHODS
The case group included 3657 patients with myocardial infarction and the control group comprised 1211 individuals with angiographically normal coronary arteries and without clinical signs or symptoms of myocardial infarction. Nine different polymorphisms were genotyped with the use of the TaqMan technique.


RESULTS
Genotype, allele, and haplotype analyses did not reveal significant associations between the polymorphisms and myocardial infarction. The negative results included a four-marker haplotype, termed HapA haplotype (odds ratio = 1.10; 95% confidence interval: 0.96-1.25), that was previously found to be related with myocardial infarction in a sample from Iceland, and a different four-marker haplotype, termed HapB haplotype (odds ratio = 0.94; 95% CI: 0.79-1.12), that was previously linked with myocardial infarction in a sample from the United Kingdom. Nine-marker haplotypes were not significantly associated with myocardial infarction in multiple logistic regression models adjusted for covariates (P >or= 0.38).


CONCLUSIONS
In this sample from central Europe, specific polymorphisms in the gene for 5-lipoxygenase-activating protein were not associated with myocardial infarction, a result contrasting previous positive findings.
Koch
Werner
W
Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. wkoch@dhm.mhn.de
Hoppmann
Petra
P
Mueller
Jakob C
JC
Schömig
Albert
A
Kastrati
Adnan
A
D058927:5-Lipoxygenase-Activating Proteins; D000368:Aged; D002352:Carrier Proteins / Q000235:genetics*; D016022:Case-Control Studies; D017931:DNA Primers; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D005858:Germany / Q000453:epidemiology; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D016015:Logistic Models; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000235:genetics* / Q000473:pathology; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*
D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; D002352:Carrier Proteins; D017931:DNA Primers; D008565:Membrane Proteins